Via Mavupharma takeout, AbbVie gets first-in-class STING target

The acquisition of Mavupharma gives AbbVie a first-in-class indirect STING booster close to the clinic that inhibits a target unexploited by other companies in oncology.

James Topper of Frazier Healthcare Partners, which led three-year-old Mavupharma Inc.’s $20 million series A round in late 2017, told BioCentury he believes this is the first foray for AbbVie Inc. (NYSE:ABBV) into the STING pathway. AbbVie, which declined to comment, also did not disclose financial terms of the deal (see “Mavupharma Raises $20M Series A for STING”)...